Group | No previous cardiovascular event | Previous cardiovascular event | ||||
---|---|---|---|---|---|---|
Generic | Brand-name | p | Generic | Brand-name | p | |
Number of patients, % | N = 8292 (77.1%) | N = 2457 (22.9%) | N = 1280 (78.0%) | N = 550 (22.0%) | ||
Sociodemographics | ||||||
Age, mean (SD), years | 59.9 (11.3) | 60.1 (11.6) | 0.427 | 67.0 (9.6) | 67.2 (10.3) | 0.640 |
Sex (female) | 54.5% | 54.9% | 0.681 | 44.1% | 42.9% | 0.630 |
Comorbidity | ||||||
Number of comorbidities | 6.3 (3.2) | 6.4 (3.5) | 0.198 | 7.5 (3.4) | 7.8 (4) | 0.087 |
Charlson index | 0.6 (1.0) | 0.6 (0.9) | 0.675 | 1.2 (1.0) | 1.3 (1.1) | 0.935 |
RUB | 2.9 (0.7) | 2.9 (0.7) | 0.485 | 3.3 (0.8) | 3.3 (0.8) | 0.755 |
Adherence | ||||||
Medication possession ratio (%) | 59.4% | 62.6% | p = 0.015 | 71.0% | 76.0% | p = 0.002 |
Treatment persistence (%, HR)* | 17.0% | 22.8% | 0.86 [0.82–0.91]; p < 0.001 | 36.1% | 42.0% | 0.88 [0.78–0.99]; p = 0.034 |
Patients who have reached LDL-c goal (%)** | ||||||
At the start of statin therapy | 18.5 [17.7–19.3] | 18.8 [17.3–20.3] | 0.710 | 14.1 [12.2–16.0] | 13.6 [10.8–16.5] | 0.764 |
At discontinuation | 37.2 [36.2–38.2] | 39.4 [37.5–41.3] | OR; 0.89 [0.80–0.99]; p = 0.025 | 48.0 [45.2–50.7] | 53.5 [49.3–57.6] | OR; 0.78 [0.64–0.95]; p = 0.015 |
Absolute variation | 18.7 | 20.6 | 0.035 | 33.8 | 39.8 | 0.014 |
Patient Outcomes (IR)*** | ||||||
- Cardiovascular event | 29.08 [26.82–31.50] | 24.69 [21.06–28.77] | 0.062 | 74.42 [67.89–81.42] | 55.41 [45.41–66.96] | 0.006 |
- All-cause mortality | 20.51 [18.61–22.55] | 16.86 [13.88–20.29] | 0.064 | 39.71 [34.98–44.91] | 26.41 [19.67–34.73] | 0.007 |
Costs (€)**** | Generic | Brand-name | Difference | Generic | Brand-name | Difference |
Healthcare costs | 8365 [8285–8445] | 7751 [7584–7918] | 614 [432–796]; p < 0.001 | 12,081 [11890–12,271] | 10,421 [10078–10,763] | 1660 [1280–2040]; p < 0.001 |
Productivity losses | 1101 [1047–1156] | 981 [873–1089] | 120 [12–232]; p = 0.068 | 15,337 [14443–16,230] | 14,890 [13007–16,773] | 447 [117–777]; p = 0.683 |
Total costs | 9466 [9368–9565] | 8732 [8536–8928] | 734 [516–952]; p = 0.001 | 27,417 [26523–28,311] | 25,310 [23512–27,110] | 2107 [1805–2409]; p < 0.001 |